BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1512 related articles for article (PubMed ID: 25274302)

  • 1. Programmable RNA recognition and cleavage by CRISPR/Cas9.
    O'Connell MR; Oakes BL; Sternberg SH; East-Seletsky A; Kaplan M; Doudna JA
    Nature; 2014 Dec; 516(7530):263-6. PubMed ID: 25274302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9.
    Sternberg SH; Redding S; Jinek M; Greene EC; Doudna JA
    Nature; 2014 Mar; 507(7490):62-7. PubMed ID: 24476820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR-Cas9 Structures and Mechanisms.
    Jiang F; Doudna JA
    Annu Rev Biophys; 2017 May; 46():505-529. PubMed ID: 28375731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA.
    Fonfara I; Richter H; Bratovič M; Le Rhun A; Charpentier E
    Nature; 2016 Apr; 532(7600):517-21. PubMed ID: 27096362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA-dependent RNA targeting by CRISPR-Cas9.
    Strutt SC; Torrez RM; Kaya E; Negrete OA; Doudna JA
    Elife; 2018 Jan; 7():. PubMed ID: 29303478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational control of DNA target cleavage by CRISPR-Cas9.
    Sternberg SH; LaFrance B; Kaplan M; Doudna JA
    Nature; 2015 Nov; 527(7576):110-3. PubMed ID: 26524520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas "Non-Target" Sites Inhibit On-Target Cutting Rates.
    Moreb EA; Hutmacher M; Lynch MD
    CRISPR J; 2020 Dec; 3(6):550-561. PubMed ID: 33346713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Basis for the Canonical and Non-canonical PAM Recognition by CRISPR-Cpf1.
    Yamano T; Zetsche B; Ishitani R; Zhang F; Nishimasu H; Nureki O
    Mol Cell; 2017 Aug; 67(4):633-645.e3. PubMed ID: 28781234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cas9 specifies functional viral targets during CRISPR-Cas adaptation.
    Heler R; Samai P; Modell JW; Weiner C; Goldberg GW; Bikard D; Marraffini LA
    Nature; 2015 Mar; 519(7542):199-202. PubMed ID: 25707807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition Mechanism of an Anti-CRISPR Suppressor AcrIIA4 Targeting SpyCas9.
    Yang H; Patel DJ
    Mol Cell; 2017 Jul; 67(1):117-127.e5. PubMed ID: 28602637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis for the PAM expansion and fidelity enhancement of an evolved Cas9 nuclease.
    Chen W; Zhang H; Zhang Y; Wang Y; Gan J; Ji Q
    PLoS Biol; 2019 Oct; 17(10):e3000496. PubMed ID: 31603896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probing the structural dynamics of the CRISPR-Cas9 RNA-guided DNA-cleavage system by coarse-grained modeling.
    Zheng W
    Proteins; 2017 Feb; 85(2):342-353. PubMed ID: 27936513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protospacer Adjacent Motif-Induced Allostery Activates CRISPR-Cas9.
    Palermo G; Ricci CG; Fernando A; Basak R; Jinek M; Rivalta I; Batista VS; McCammon JA
    J Am Chem Soc; 2017 Nov; 139(45):16028-16031. PubMed ID: 28764328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-time observation of DNA target interrogation and product release by the RNA-guided endonuclease CRISPR Cpf1 (Cas12a).
    Singh D; Mallon J; Poddar A; Wang Y; Tippana R; Yang O; Bailey S; Ha T
    Proc Natl Acad Sci U S A; 2018 May; 115(21):5444-5449. PubMed ID: 29735714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis of stringent PAM recognition by CRISPR-C2c1 in complex with sgRNA.
    Wu D; Guan X; Zhu Y; Ren K; Huang Z
    Cell Res; 2017 May; 27(5):705-708. PubMed ID: 28374750
    [No Abstract]   [Full Text] [Related]  

  • 16. In Vitro Reconstitution and Crystallization of Cas9 Endonuclease Bound to a Guide RNA and a DNA Target.
    Anders C; Niewoehner O; Jinek M
    Methods Enzymol; 2015; 558():515-537. PubMed ID: 26068752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guide RNA functional modules direct Cas9 activity and orthogonality.
    Briner AE; Donohoue PD; Gomaa AA; Selle K; Slorach EM; Nye CH; Haurwitz RE; Beisel CL; May AP; Barrangou R
    Mol Cell; 2014 Oct; 56(2):333-339. PubMed ID: 25373540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding the Biologist's Toolkit with CRISPR-Cas9.
    Sternberg SH; Doudna JA
    Mol Cell; 2015 May; 58(4):568-74. PubMed ID: 26000842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of genome editing through CRISPR-Cas9 engineering.
    Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
    Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coordinated Actions of Cas9 HNH and RuvC Nuclease Domains Are Regulated by the Bridge Helix and the Target DNA Sequence.
    Babu K; Kathiresan V; Kumari P; Newsom S; Parameshwaran HP; Chen X; Liu J; Qin PZ; Rajan R
    Biochemistry; 2021 Dec; 60(49):3783-3800. PubMed ID: 34757726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 76.